RxDoctor Payments Data

Katrina McCoy, APRN

Family · Brandenburg, KYNPI 1205162047

Payments from drug & device makers

$1,306in general payments, 2019–2025

Across 78 payments — averaging $16.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$437
  • Novo Nordisk$304
  • Lilly USA, LLC$155
  • AstraZeneca$140
  • Pfizer$112
  • Biohaven Pharmaceutical Holding Company Ltd.$48
  • plus $109 from 6 others

What the payments were for

  • Food & beverage$1,306100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,306 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$28,388
Medicare patients
111
Services billed
494

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide54$63,719
FarxigaDapagliflozin Propanediol93$57,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter77$48,409
MounjaroTirzepatide34$35,231
EliquisApixaban32$32,226
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$19,916
Nurtec OdtRimegepant Sulfate11$10,284
Breo ElliptaFluticasone/Vilanterol16$8,006
DapagliflozinDapagliflozin Propanediol15$7,386
LinzessLinaclotide12$6,213
Albuterol Sulfate HfaAlbuterol Sulfate182$5,873
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,227
SymbicortBudesonide/Formoterol Fumarate12$2,763
Novolog FlexpenInsulin Aspart11$2,547
PremarinEstrogens, Conjugated12$2,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$140$80,624134 claims
Novo NordiskOzempic$304$63,71954 claims
GSKTrelegy Ellipta, Breo Ellipta$18$56,41593 claims
PfizerEliquis, Nurtec Odt, Premarin$112$45,03855 claims
Lilly USA, LLCMounjaro$155$35,23134 claims
AbbVieLinzess$437$6,21312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.

Other family in Brandenburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →